文献速递消化内镜消化道肿瘤与早癌

内镜黏膜下剥离术治疗肛管病变的可行性与安全性

Feasibility and safety of endoscopic submucosal dissection for the anal canal lesions.
PubMed 文献 · Gastrointest Endosc · 2025-06-30

该研究回顾性分析102例肛管病变患者接受ESD的结果,整块切除率94.1%,整块联合R0切除率88.2%,中位随访37个月局部复发3例。累及齿状线组手术时间更长、标本更大、整块联合R0切除率更低、肛门疼痛和不良事件更多。

要点

  • ESD治疗肛管病变整块切除率94.1%,整块联合R0切除率88.2%。
  • 累及齿状线组整块联合R0切除率更低、肛门疼痛和不良事件更多。
  • 仅分析腺瘤/腺癌时,两组无复发生存、总生存和疾病特异生存无显著差异。

核心结论

  • ESD治疗肛管病变具有良好的短期和长期结局,是安全、有效且有吸引力的治疗方式。

研究设计与样本

  • 回顾性研究纳入2010年8月至2023年8月接受ESD的102例肛管病变患者,平均年龄63岁,男性46例。

主要发现

  • 平均手术时间37.0分钟,整块切除率94.1%,整块联合R0切除率88.2%。
  • 不良事件包括术中出血2例、迟发出血2例、发热1例,肛门疼痛5例。
  • 中位随访37个月,局部复发3例,转移1例。
  • 与齿状线以上组相比,累及齿状线组手术时间更长、标本更大、整块联合R0切除率更低、肛门疼痛率更高、不良事件更多。
  • 仅纳入腺瘤/腺癌分析时,两组无复发生存、总生存和疾病特异生存无显著差异。

临床怎么用

  • ESD可作为肛管病变的治疗选择,但累及齿状线者需注意整块联合R0切除率较低及不良事件风险较高。

局限性

  • 为单中心回顾性研究,需多中心前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: We aimed to evaluate the technical safety, efficacy, and feasibility of endoscopic submucosal dissection (ESD) for anal canal lesions (ACLs) and compare outcomes between lesions involving the dentate line (IDL) and those above the dentate line (ADL) to guide clinical decision-making. METHODS: We retrospectively investigated 102 patients with ACLs who underwent ESD from August 2010 to August 2023. We collected and analyzed clinicopathologic characteristics, procedure-related parameters, outcomes, and follow-up data. RESULTS: Of the 102 patients with ACLs (mean age 63 years, 46 men), ADLs were in 55 patients, and IDLs were in 47. The mean procedure duration was 37.0 minutes. The en bloc resection and en bloc with R0 resection rates were 94.1% and 88.2%, respectively. Adverse events included 2 intraoperative bleeding, 2 delayed bleeding, and 1 episode of febrility. Anal pain occurred in 5 patients. During a median follow-up of 37 months, local recurrence was revealed in 3 patients, and 1 had metastases. Compared with the ADL group, the involving dentate line group had significantly longer procedure duration, larger specimens, lower rates of en bloc with R0 resection, greater rates of anal pain, and more adverse events. When only adenomas/adenocarcinomas were included in the analysis, the 2 groups had no significant differences regarding recurrence-free, overall, and disease-specific survival. CONCLUSIONS: The favorable short- and long-term outcomes indicate ESD is a safe, effective, and attractive therapeutic modality for ACLs. A multicenter and prospective study should be conducted to validate this technology.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Wang L, Du L, Liu ZQ, et al. Feasibility and safety of endoscopic submucosal dissection for the anal canal lesions. Gastrointest Endosc. 2025. PMID: 40602731. doi:10.1016/j.gie.2025.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。